Form 4: Prothena Director William H. Dunn Jr. Receives Stock Options
Statement of Changes in Beneficial Ownership
Director William H. Dunn Jr. was granted 27,000 stock options in Prothena Corporation as part of standard equity compensation.
Summary
- Director William H. Dunn Jr. received a grant of 27,000 stock options on May 15, 2026.
- The options have an exercise price of $9.76 per share.
- The options are set to expire on May 15, 2036.
- Vesting is scheduled for the earlier of the first anniversary of the grant date or the 2027 annual general meeting, contingent on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market volatility affecting the value of the granted options.
- Dependence on continued director service for vesting.
Future Outlook
The options vest in full on the earlier of the first anniversary of the grant date or the 2027 annual general meeting, assuming continuous service.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.
Comparison to Industry Standards
- The grant structure follows standard industry practices for director compensation in mid-cap biotech firms.
- Vesting schedules tied to annual general meetings are common among publicly traded companies to align director tenure with shareholder cycles.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options on the earlier of May 15, 2027, or the 2027 annual general meeting.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Transaction date of the stock option grant. |
| 05/15/2036 | Expiration date of the granted stock options. |
Keywords
Prothena, PRTA, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.